Bristol-Myers Squibb (BMY) shares recently closed at US$63.88, trading below a Discounted Cash Flow (DCF) model's estimated intrinsic value. The company generated approximately $11.5 billion in free cash flow over the last twelve months, with forecasts projecting a mature profile featuring an initial step-up followed by a decline over the next decade.
Analysts at Simply Wall St present diverging narratives regarding the stock's valuation. A bullish case suggests BMY is 22% undervalued, citing breakthrough partnerships like the BioNTech deal that position the company for leadership in immuno-oncology and radiopharmaceuticals. Conversely, a bearish view argues the stock is 30% overvalued due to impending revenue cliffs associated with the loss of exclusivity for major blockbusters such as Eliquis, Opdivo, and Revlimid after 2026.
Recent clinical progress continues to influence investor sentiment regarding BMY's future cash flows. Positive Phase 3 data for ZENBEXUS in multiple myeloma has strengthened the case for ongoing oncology revenue, while broader efforts in immunology are expected to shift the company's revenue mix and investment needs over time.
📉 Stock trades below DCF intrinsic value despite mature free cash flow of $11.5 billion.
🤝 BioNTech partnership supports bullish view with 22% undervaluation rating in immuno-oncology.
⚠️ Bearish outlook cites 30% overvaluation due to post-2026 revenue cliffs from Eliquis and Opdivo.
🧬 Positive Phase 3 EXCALIBER-RRMM data for ZENBEXUS strengthens oncology cash flow outlook.
📈 Stock gained 51.6% last year driven by new drug data and expanding pipeline.
📉 BMY stock closed at US$63.88, trading below a DCF model's intrinsic value estimate which implies a discount to future cash generation.
💰 The company produced roughly $11.5 billion in free cash flow over the last twelve months with a forecasted mature profile.
🤝 A bullish narrative rates BMY as 22% undervalued, highlighting the BioNTech partnership for industry leadership in immuno-oncology.
⚠️ A bearish narrative rates BMY as 30% overvalued due to severe revenue cliffs expected after 2026 from patent expirations on Eliquis, Opdivo, and Revlimid.
🧬 Recent positive Phase 3 EXCALIBER-RRMM data for ZENBEXUS strengthens the outlook for oncology cash flows.
📈 BMY delivered a 51.6% gain over the past year driven by fresh drug data and an expanding pipeline.
Bullish Signals
Generated $11.5 billion free cash flow last twelve months.
Positive EXCALIBER-RRMM data strengthens oncology revenue case.
Bristol Myers Squibb (BMY) shares closed at USD 63.88 on September 28, 2026, representing a gain of USD 1.02 or 1.62% from the previous session's close of USD 62.86. The stock traded on the New York Stock Exchange as of 20:00:02 UTC.
On September 25, 2026, the company announced positive Phase 3 trial results for its multiple myeloma candidate ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone. The EXCALIBER-RRMM trial evaluated the treatment in 420 patients with relapsed or refractory disease.
The study demonstrated a minimal residual disease-negative complete response rate of 41.10% for the ZENBEXUS combination, compared to 20.70% for the comparator regimen of daratumumab, bortezomib, and dexamethasone. These results were presented at the 2026 International Myeloma Society meeting and published in The Lancet Oncology.
Additionally, Bristol Myers Squibb's board declared a quarterly dividend of USD 0.63 per share on September 16, 2026. This dividend is scheduled to be payable on November 2, 2026, to shareholders of record as of October 2, 2026.
📈 BMY stock closed at $63.88, up 1.62% on September 28, 2026.
💰 BMY declared $0.63 quarterly dividend payable November 2, 2026.
📈 BMY stock closed at USD 63.88 on September 28, 2026, up 1.62% from the prior session.
🔬 Bristol Myers Squibb announced Phase 3 EXCALIBER-RRMM trial results for ZENBEXUS in multiple myeloma.
📊 The ZENBEXUS combination achieved a 41.10% minimal residual disease-negative complete response rate versus 20.70% for the comparator.
📅 Trial data was presented at the 2026 International Myeloma Society meeting and published in The Lancet Oncology.
💰 The company declared a quarterly dividend of USD 0.63 per share payable on November 2, 2026.
Bullish Signals
ZENBEXUS Phase 3 showed 41.10% response rate vs 20.70%.
Stock rose 1.62% to USD 63.88 after trial results.
Bullish Signals
Bristol Myers Squibb reported positive Phase 3 data for ZENBEXUS in multiple myeloma, showing a 41.10% complete response rate versus 20.70% for the comparator.
The company's stock price increased by 1.62% to close at USD 63.88 following the announcement of clinical trial results.
On September 1, 2026, Bristol-Myers Squibb (BMY) paused enrollment in its competing CAR-T program, zola-cel, for autoimmune and neurological conditions. The company cited precautionary measures following observations of 'transient and reversible' inflammatory events, explicitly noting that no patient deaths occurred during this period.
Unlike Novartis, which halted eight trials after three patient deaths from a severe immune reaction, BMY's response is narrower in scope and severity. The firm has not stopped all aspects of its trials but rather limited new enrollment while conducting a safety review to identify effective monitoring or treatment strategies that could allow for a restart.
Market positioning data reveals a divergence in investor sentiment ahead of the public disclosure. Hedge fund interest in BMY declined significantly, with holder counts dropping from 83 to 74 and position value falling from $5.97 billion to $4.79 billion in the second quarter, contrasting with Novartis which saw increased hedge fund accumulation prior to its own setbacks becoming public.
🛑 BMY paused zola-cel enrollment due to transient inflammatory events.
💀 No patient deaths reported for BMY's zola-cel trials.
📉 Hedge fund interest in BMY dropped from $5.97B to $4.79B.
⏳ BMY paused only new enrollment, not all trial activities.
⚖️ BMY faced governance concerns over three-month disclosure delay.
🛑 Bristol-Myers Squibb paused enrollment in its zola-cel autoimmune CAR-T program following observations of transient and reversible inflammatory events.
💀 No patient deaths were reported for BMY's zola-cel trials, distinguishing the safety profile from Novartis' recent fatal immune reactions.
📉 Hedge fund interest in BMY decreased in Q2 2026, with position value dropping from $5.97 billion to $4.79 billion as investors reacted to pipeline uncertainty.
⏳ The company paused only new enrollment rather than halting all trial activities, suggesting a potentially clearer path toward restarting studies if safety protocols are adjusted.
🔬 BMY described the inflammatory events as transient and reversible, indicating a less severe disclosed safety situation compared to Novartis' fatal cases.
⚖️ The pause creates governance concerns regarding disclosure timelines, as BMY waited three months before informing the public despite early June internal notifications.
Bullish Signals
Safety events were transient and reversible.
Trial paused only new enrollment, not all.
Risk Factors
Enrollment paused due to inflammatory events causing delays.
Safety issues delayed public disclosure for three months.
Hedge fund positions dropped from $5.97B to $4.79B.
Bullish Signals
The company reported that observed inflammatory events were transient and reversible, suggesting a manageable safety profile compared to fatal outcomes seen in competitors.
Bristol-Myers Squibb paused only new enrollment rather than stopping all trial activities, preserving ongoing data collection and offering a clearer path toward restarting studies.
Risk Factors
Enrollment was paused in the zola-cel autoimmune CAR-T program following observations of inflammatory events, creating immediate development delays.
The company waited approximately three months to inform the public about safety issues despite internal knowledge in early June, raising governance and reputational concerns.
Hedge fund interest declined significantly in Q2 2026, with position value dropping from $5.97 billion to $4.79 billion, reflecting investor caution regarding pipeline setbacks.
Bristol Myers Squibb (BMY) shares traded on the NYSE on September 25, 2026, closing at USD 61.93, representing a gain of 0.71 percent or USD 0.43 from the prior session's reference price. The stock opened at USD 61.75 and fluctuated between an intraday low of USD 61.39 and a high of USD 62.28 before settling near the upper end of its range. Trading volume for the session stood at approximately 3.97 million shares, indicating moderate liquidity as the stock outperformed the broader S&P 500 ETF (SPY) by 0.24 percentage points.
A significant catalyst driving the positive sentiment was an analyst upgrade from Zacks Research, which changed the rating on BMY from 'hold' to 'strong buy' earlier that day. This upgrade provides a bullish signal regarding the company's future prospects and valuation relative to peers. Additionally, the board declared a quarterly dividend of USD 0.63 with a record date set for October 2, 2026, and an expected payment date of November 2, 2026, offering income support to shareholders.
The broader market context included easing oil prices and Treasury yields, which left defensive healthcare stocks mixed despite major index futures pointing higher. While peers like Pfizer, Merck, and Eli Lilly saw declines or stagnation during the session, BMY managed to post a gain. The company is preparing to report its third-quarter 2026 financial results on October 29, 2026, with a conference call scheduled for 8:00 a.m. ET.
Current pricing places BMY at USD 61.93, which is 9.78 percent below its 52-week high of USD 68.64 but 45.65 percent above its 52-week low of USD 42.52. The stock's performance suggests resilience in a mixed market environment, bolstered by the combination of an analyst upgrade and upcoming dividend distribution. Investors are likely monitoring the upcoming earnings report for further guidance on revenue and margin trends.
📈 Shares rose 0.71% to USD 61.93, outperforming S&P 500.
🚀 Zacks upgraded stock from 'hold' to 'strong buy'.
💰 Declared quarterly dividend of USD 0.63.
📊 Volume hit 3.97M shares; price range USD 61.39-62.28.
🗓️ Q3 2026 earnings scheduled for October 29, 2026.
📈 Bristol Myers Squibb shares rose 0.71 percent to USD 61.93, outperforming the S&P 500 ETF by 0.24 percentage points in New York trading.
🚀 Zacks Research upgraded BMY from 'hold' to 'strong buy', providing a positive analyst sentiment signal for the stock.
💰 The company declared a quarterly dividend of USD 0.63 with an October 2, 2026 record date and November 2 payment date.
📊 Trading volume reached 3,974,531 shares as the stock traded between USD 61.39 and USD 62.28 during the session.
📉 BMY is currently trading 9.78 percent below its 52-week high of USD 68.64 but remains well above its 52-week low.
🗓️ The company is scheduled to report third-quarter 2026 earnings on October 29, 2026, with a conference call at 8:00 a.m. ET.
⚖️ While peers like Pfizer and Merck declined during the session, BMY maintained positive momentum amidst mixed defensive healthcare sentiment.
Bullish Signals
Zacks upgraded shares from 'hold' to 'strong buy'.
Stock gained 0.71% to USD 61.93.
Board declared quarterly dividend of USD 0.63.
Bullish Signals
Zacks Research upgraded Bristol Myers Squibb shares from 'hold' to 'strong buy', signaling improved analyst confidence in the company's prospects.
The stock gained 0.71 percent to USD 61.93, outperforming the broader S&P 500 ETF (SPY) by 0.24 percentage points during the trading session.
The board declared a quarterly dividend of USD 0.63 with a record date of October 2, 2026, providing income support to shareholders.
The article compares Bristol Myers Squibb (BMY) and Pfizer, noting BMY's focus on oncology and immunology versus Pfizer's transformation into high-growth areas like obesity. In fiscal year 2025, BMY reported revenue of nearly $48.2 billion, a slight decline of 0.2%, with net income of approximately $7.1 billion and a net margin of 14.6%. This performance marks a recovery from the previous year's net loss.
Bristol Myers Squibb maintains a debt-to-equity ratio of 2.6x and a current ratio of 1.3x, with free cash flow reaching roughly $12.8 billion. The company faces challenges including pricing pressure from government mandates, patent expirations on blockbuster drugs, and ongoing litigation involving a $6.7 billion legal challenge and a lawsuit from Cytokinetics.
Analysts suggest BMY is a compelling near-term bet due to raised full-year revenue outlooks and impressive growth in newer brands, with Eliquis defying expectations. However, the article notes that BMY was not included in The Motley Fool Stock Advisor's list of top 10 stocks for immediate purchase, contrasting its short-term strength with Pfizer's longer-term transformational potential.
📈 FY 2025 revenue reached $48.2B with a slight 0.2% decline.
💰 Net income hit $7.1B, yielding a 14.6% net margin.
📉 Debt-to-equity ratio stands at 2.6x as of December 2025.
Bristol Myers Squibb (BMY) reported second-quarter 2026 financial results that exceeded market consensus, driving a modest 0.1 percent gain in its share price to close at USD 62.68 on the NYSE. The company posted quarterly earnings per share of USD 2.04, significantly beating the USD 1.60 analyst estimate by USD 0.44, while revenue increased 5.7 percent year over year to reach USD 12.97 billion.
Despite the strong operational performance and a concrete earnings anchor provided by the beat, the stock traded below its 52-week high of USD 68.64, remaining USD 5.96 away from that peak. The market reaction was muted with a volume of 2,184,600 shares, suggesting investors are weighing current profitability against future capital requirements.
Looking ahead to fiscal year 2026, the company provided adjusted EPS guidance ranging between USD 6.75 and USD 7.00, which aligns closely with analyst consensus expectations of USD 6.95. However, management increased its full-year operating expense projection to approximately USD 16.5 billion due to pre-launch activities and development programs, indicating a strategic investment in future growth that impacts near-term margins.
The valuation backdrop shows BMY trading at a price-to-earnings ratio of 13.80 with a market capitalization of USD 128.04 billion. The central tension for investors lies in the company's ability to sustain revenue growth and EPS beats while funding significant operating investments required for upcoming product launches.
📈 BMY Q2 2026 revenue rose 5.7% to USD 12.97 billion.
💰 Non-GAAP EPS hit USD 2.04, beating estimates by USD 0.44.
🔮 FY 2026 adjusted EPS guidance set between USD 6.75 and USD 7.00.
💸 Full-year 2026 operating expenses increased to approximately USD 16.5 billion.
📉 Stock closed at USD 62.68, trading below its 52-week high.
📈 Bristol Myers Squibb reported second-quarter 2026 revenue of USD 12.97 billion, representing a 5.7 percent year-over-year increase.
💰 Non-GAAP earnings per share reached USD 2.04, exceeding the consensus estimate of USD 1.60 by USD 0.44.
📉 The stock closed at USD 62.68 on September 22, 2026, trading below its 52-week high of USD 68.64 despite the earnings beat.
🔮 Fiscal year 2026 adjusted EPS guidance was set between USD 6.75 and USD 7.00, aligning with analyst consensus of USD 6.95.
💸 Operating expenses for full-year 2026 were increased to approximately USD 16.5 billion due to pre-launch activity and development programs.
📊 The company trades at a price-to-earnings ratio of 13.80 with a market capitalization of USD 128.04 billion.
Bullish Signals
Q2 2026 revenue hit $12.97B, up 5.7% YoY.
Non-GAAP EPS of $2.04 beat estimates by $0.44.
FY2026 adjusted EPS guidance covers consensus at $6.95.
Risk Factors
Operating expenses projected to rise to USD 16.5 billion in 2026.
Stock closed at USD 62.68, down from 52-week high of USD 68.64.
Bullish Signals
Bristol Myers Squibb reported second-quarter 2026 revenue of USD 12.97 billion, marking a 5.7 percent year-over-year increase.
Non-GAAP earnings per share reached USD 2.04, significantly beating the consensus estimate of USD 1.60 by USD 0.44.
The company provided fiscal year 2026 adjusted EPS guidance between USD 6.75 and USD 7.00, which encompasses the analyst consensus expectation of USD 6.95.
Risk Factors
Management increased its projection for full-year 2026 operating expenses to about USD 16.5 billion due to pre-launch activity and development programs.
The stock closed at USD 62.68, trading USD 5.96 below its 52-week high of USD 68.64 despite the positive earnings surprise.
Bristol Myers Squibb (BMY) has officially discontinued the development of BMS-986497/ORM-6151, a Phase 1 cancer candidate it licensed from Orum Therapeutics. The asset, described as a degrader-antibody conjugate, was part of a licensing agreement with a headline value referenced at $100 million. The discontinuation was confirmed via a regulatory filing on Thursday, marking the end of human testing for this specific early-stage molecule.
The decision represents a routine portfolio management move rather than a significant corporate setback or existential crisis for the large-cap pharmaceutical company. Bristol Myers Squibb operates with more oncology candidates than it can fund to registration, leading to the pruning of early pipelines. Consequently, the discontinuation does not impact near-term revenue and carries no direct read-through to the company's late-stage programs or overall financial health.
Market reaction to the news was neutral to slightly positive, with BMY shares trading up 0.35% to close at $63.06. Investors appear to have treated the filing as standard housekeeping consistent with the company's scale and development capacity constraints. The move signals a choice regarding where scarce resources are allocated but does not invalidate the broader scientific architecture of degrader-antibody conjugates.
The discontinuation specifically impacts Orum Therapeutics, which retains any cash already paid but loses access to future milestone payments contingent on advancing past Phase 1. For BMY, the primary implication is a reduction in pipeline breadth at an early stage without affecting its core business operations or stock performance.
📉 Bristol Myers Squibb discontinued Phase 1 cancer program BMS-986497/ORM-6151.
💰 Discontinuation prevents future milestone payments from the $100 million licensing deal.
📊 Shares rose 0.35% to $63.06 as investors view cut as routine management.
⚖️ Decision maintains stable stock status with no impact on late-stage oncology.
📉 Bristol Myers Squibb has discontinued development of BMS-986497/ORM-6151, a Phase 1 degrader-antibody conjugate cancer program licensed from Orum Therapeutics.
💰 The asset was part of a licensing deal referenced at $100 million, though the discontinuation prevents the realization of future milestone payments tied to advancement beyond Phase 1.
📊 BMY shares closed higher at $63.06 (up 0.35%), indicating investors viewed the pipeline cut as routine portfolio management rather than a negative financial event.
🔬 The discontinued molecule utilized a novel payload architecture designed to hijack cellular disposal machinery, representing a variation on the crowded antibody-drug conjugate field.
🏢 As a large pharmaceutical company, Bristol Myers Squibb routinely prunes early-stage candidates that do not meet high bar standards for advancing past Phase 1 into registration.
⚖️ The decision does not alter BMY's near-term revenue or signal any issues with its late-stage oncology programs, maintaining the status of the stock as stable.
Bullish Signals
Shares rose 0.35% to $63.06, showing investor confidence in pipeline cut.
Early-stage asset drop won't affect near-term revenue or late-stage programs.
Risk Factors
BMS-986497/ORM-6151 development terminated in Phase 1.
Future milestone payments for this asset lost.
Bullish Signals
Bristol Myers Squibb shares closed up 0.35% at $63.06, reflecting investor confidence that the pipeline cut is a routine portfolio management decision rather than a setback.
The discontinuation of an early-stage Phase 1 asset has no impact on the company's near-term revenue or its late-stage program portfolio.
Risk Factors
Bristol Myers Squibb has terminated development of BMS-986497/ORM-6151, a licensed degrader-antibody conjugate candidate in Phase 1 human testing.
The discontinuation means the company will not realize future milestone payments contingent on advancing this specific asset beyond Phase 1.
Bristol-Myers Squibb (BMY) shares closed at USD 62.84 on September 17, 2026, trading approximately 8.4% below their 52-week high but well above the low. The company reported strong second-quarter 2026 financial performance with revenue rising 5.7% year-over-year and achieving a profit margin of 25.57%. These solid operational metrics provided a quantitative counterweight to recent negative developments in its drug development pipeline, helping to stabilize investor sentiment despite the halt on specific assets.
The primary headwind for BMY involves the discontinuation of ORM-6151, a blood cancer candidate licensed from Orum Therapeutics. After reviewing early Phase 1 clinical data, Bristol-Myers Squibb decided to return development rights to the biotech partner, ending a program where it had previously committed USD 100 million. While this setback negatively impacted Orum Therapeutics' stock price by over 33%, analysts view the impact on BMY as contained due to the depth of its broader oncology and immunology portfolios.
From a valuation perspective, BMY trades at a significant discount to the broader large-cap pharmaceutical industry, with a forward price-to-earnings ratio of 9.58 times compared to an industry average of 18.01 times. The stock has gained 16.5% year-to-date, outpacing the broader industry's 5.7% growth, suggesting investors have already rewarded the company for its operational delivery. Analyst consensus remains constructive with rising earnings estimates for 2026 and 2027, though the Zacks Rank is currently a 'Hold' pending further pipeline progress.
Looking ahead, the next scheduled earnings release is set for October 29, 2026. With a market capitalization of approximately USD 129.46 billion, BMY remains a core constituent of the S&P 500 Health Care sector. Investors are weighing the near-term pipeline volatility against the company's attractive valuation and strong mid-single-digit revenue growth, positioning the stock in the upper half of its 52-week trading range.
📉 BMY shares closed at USD 62.84, trading 8.4% below the 52-week high.
💰 Q2 2026 revenue rose 5.7% with a robust 25.57% profit margin.
🚫 BMY discontinued ORM-6151 development and returned rights to Orum Therapeutics.
📊 Stock trades at forward P/E of 9.58x, well below industry average.
🚀 Shares gained 16.5% year-to-date, outperforming the broader pharmaceutical sector.
📉 BMY shares closed at USD 62.84 on September 17, 2026, trading 8.4% below the 52-week high but significantly above the low.
💰 Q2 2026 revenue increased by 5.7% with a robust profit margin of 25.57%, demonstrating strong operational efficiency.
🚫 The company discontinued development of ORM-6151 and returned rights to Orum Therapeutics after reviewing Phase 1 data.
💸 BMY had previously committed USD 100 million to the ORM-6151 degrader-antibody conjugate program before pulling back.
📊 The stock trades at a forward P/E of 9.58x, which is substantially lower than the industry average of 18.01x.
🚀 Shares have gained 16.5% year-to-date, outperforming the broader pharmaceutical industry's 5.7% growth rate.
📈 Analyst consensus estimates for 2026 earnings per share rose to USD 6.91 from USD 6.34 over the past 60 days.
🗓️ The next earnings report is scheduled for release on October 29, 2026.
🏢 BMY maintains a market capitalization of approximately USD 129.46 billion as of September 18, 2026.
⚖️ The stock currently holds a Zacks Rank of 3 (Hold), reflecting a balanced analyst stance on valuation and pipeline.
Bullish Signals
Revenue grew 5.7% with 25.57% profit margin in Q2 2026.
Risk Factors
Discontinued ORM-6151 development after Phase 1 data review.
Ended $100M program commitment following pipeline asset pivot.
Bullish Signals
Bristol-Myers Squibb delivered strong Q2 2026 financial results with revenue growth of 5.7% and a profit margin of 25.57%, supporting the stock price.
The company trades at a significant valuation discount to the industry average, with a forward P/E ratio of 9.58x compared to an industry average of 18.01x.
Shares have appreciated 16.5% year-to-date, significantly outperforming the broader pharmaceutical sector's 5.7% growth.
Analyst consensus estimates for 2026 earnings per share have increased to USD 6.91, indicating constructive expectations for future performance.
The stock is trading in the upper half of its 52-week range, suggesting investor confidence despite specific pipeline setbacks.
Risk Factors
Bristol-Myers Squibb discontinued development of ORM-6151 and returned rights to Orum Therapeutics after reviewing early Phase 1 clinical data.
The company ended a program where it had previously committed USD 100 million, reflecting a strategic pivot following the review of pipeline assets.
Bristol-Myers Squibb (BMY) shares closed at USD 62.84 on September 17, 2026, reflecting a mixed market reaction where strong second-quarter financial performance was partially offset by the decision to halt development of the oncology candidate ORM-6151. The company reported Q2 2026 revenue of USD 12.97 billion, representing a 5.7% year-over-year increase that significantly beat analyst expectations by 12.9%. Earnings per share reached USD 2.04, surpassing the consensus estimate of USD 1.60 and yielding a profit margin of 25.57%.
The strategic decision to discontinue ORM-6151, a blood cancer degrader-antibody conjugate licensed from Orum Therapeutics, removes a potential future revenue stream for Bristol-Myers Squibb. This development also eliminates up to USD 80 million in contingent milestone payments owed to the partner, though the upfront payment of USD 100 million previously received remains intact. The halt follows a review of Phase 1 clinical data conducted across the United States, Europe, and Canada.
Despite the pipeline setback, the company's core portfolio continues to generate substantial cash flow, supported by a fresh dividend declaration of USD 0.63 per share with an ex-dividend date of October 2, 2026. Investors view the stock as modestly undervalued compared to peers like AbbVie, trading at a forward price-earnings multiple of 9.2 times versus 18.5 times for the competitor. The market capitalization stands at approximately USD 129.46 billion.
Looking ahead, Bristol-Myers Squibb is scheduled to release Q3 2026 results on October 29, 2026, which will provide clarity on whether the strong revenue trajectory can be sustained amidst pipeline adjustments. Additionally, a Phase 3 study for the investigational agent izalontamab brengitecan in combination with osimertinib is set to commence on September 30, 2026, highlighting the diversified nature of the research portfolio as the company manages risks associated with specific asset discontinuations.
📉 BMY stock closed at $62.84, trading 8.4% below its 52-week high.
💰 Q2 2026 revenue hit $12.97 billion, beating estimates by 12.9%.
📊 EPS reached $2.04, exceeding consensus with a 25.57% profit margin.
⚠️ BMY halted ORM-6151 development, saving up to $80 million in milestones.
📈 Board declared a $0.63 cash dividend with an ex-date of Oct 2.
📉 Bristol-Myers Squibb stock closed at USD 62.84 on September 17, 2026, trading roughly 8.4% below its 52-week high of USD 68.64.
💰 The company reported Q2 2026 revenue of USD 12.97 billion, up 5.7% year over year and beating analyst expectations by 12.9%.
📊 Earnings per share reached USD 2.04, exceeding the consensus estimate of USD 1.60 with a profit margin of 25.57%.
⚠️ Bristol-Myers Squibb decided to halt development of ORM-6151, a blood cancer candidate licensed from Orum Therapeutics, after reviewing Phase 1 data.
💸 The discontinuation of ORM-6151 eliminates up to USD 80 million in contingent milestone payments for the partner company.
📈 The board declared a cash dividend of USD 0.63 per share with an ex-dividend date of October 2, 2026.
🔬 A Phase 3 study for izalontamab brengitecan in combination with osimertinib is scheduled to start on September 30, 2026.
📉 Bristol-Myers Squibb trades at a forward price-earnings multiple of 9.2 times, significantly lower than peer AbbVie's 18.5 times.
📅 The company plans to release Q3 2026 financial results on October 29, 2026.
🏥 Market capitalization is approximately USD 129.46 billion as of September 18, 2026.
Bullish Signals
Q2 2026 revenue hit USD 12.97B, beating estimates by 12.9%.
EPS reached USD 2.04, surpassing consensus by USD 0.44.
Profit margin expanded to a robust 25.57% in Q2 2026.
Board declared fresh cash dividend of USD 0.63 per share.
Analysts peg fair value at USD 66.21, suggesting undervaluation.
Bristol-Myers Squibb (BMY) shares gained momentum following the release of positive two-year clinical trial data for its immunology drug Sotyktu in psoriatic arthritis. The Phase 3 POETYK PsA-2 study and its open-label extension demonstrated durable efficacy and a consistent safety profile, with results presented at the Congress of Clinical Rheumatology - West. This development serves as a new catalyst for the company's efforts to expand Sotyktu beyond its existing indications in plaque psoriasis.
Fundamentally, Bristol-Myers Squibb reported robust second-quarter 2026 financial results that exceeded market expectations. Revenue rose 6 percent year-over-year to USD 12.97 billion, while non-GAAP earnings per share (EPS) increased to USD 2.04, beating the consensus estimate of USD 1.60 by a significant margin. The Growth Portfolio drove this expansion with a 15 percent revenue increase, whereas the Legacy Portfolio declined 4 percent due to generic erosion in oncology assets like Revlimid and Pomalyst.
The company maintains a sustainable capital return profile with a quarterly dividend of USD 0.63 per share, offering a yield of approximately 3.95 percent. Analyst consensus rates BMY as a Moderate Buy with an average target price near USD 66.71, implying upside potential from the recent trading levels around USD 63.60. However, investors must monitor ongoing generic competition pressures and valuation metrics that suggest the stock trades slightly above its intrinsic value estimate.
📈 Q2 2026 revenue rose 6% to USD 12.97 billion driven by Growth Portfolio.
💊 Sotyktu shows durable efficacy and favorable safety in POETYK PsA-2 study.
📉 Legacy Portfolio fell 4% due to generic erosion of Revlimid and Pomalyst.
💰 Quarterly dividend maintained at USD 0.63 with ~3.95% yield for shareholders.
Bristol-Myers Squibb reported Q2 2026 revenue of USD 12.97 billion, a 6 percent year-over-year increase driven by strong growth in its Growth Portfolio.
Non-GAAP EPS for the quarter reached USD 2.04, significantly beating the consensus estimate of USD 1.60 and demonstrating robust profitability.
Positive two-year clinical trial data for Sotyktu in psoriatic arthritis demonstrated durable efficacy and a consistent safety profile, serving as a new catalyst.
Eliquis revenue within the Legacy Portfolio grew 22 percent to USD 4.48 billion, highlighting the strength of the cardiovascular franchise.
The company maintained its quarterly dividend at USD 0.63 per share with a sustainable payout ratio of 39 percent and a three-year growth rate of 4.4 percent.
Risk Factors
The Legacy Portfolio declined 4 percent to USD 5.42 billion due to ongoing generic erosion affecting oncology assets Revlimid and Pomalyst.
Valuation analysis suggests the stock trades approximately 12.4 percent above its GF Value estimate, which could limit near-term upside if earnings growth slows.
Bristol Myers Squibb (BMY) announced that its Board of Directors has declared a quarterly dividend of $0.63 per share on its common stock. This declaration reinforces the company's ongoing strategy to return value to shareholders through consistent cash distributions.
The dividend is scheduled to be payable on November 2, 2026, to stockholders of record as of the close of business on October 2, 2026. This payment maintains the established cadence of quarterly distributions previously set by the company.
Alongside the financial announcement, Bristol Myers Squibb reiterated its core mission to discover, develop, and deliver innovative medicines for serious diseases. The company emphasized that this commitment is supported by continued investment in research and bold scientific advancements across its global portfolio.
📈 BMY declared $0.63 quarterly dividend payable Nov 2, 2026.
📅 Record date is October 2, 2026 for eligible shareholders.
💰 Move reinforces strategy of returning value via cash distributions.
🔬 Company reaffirms mission to deliver innovative medicines globally.
📈 BMY declared a quarterly dividend of $0.63 per share on common stock.
📅 The dividend will be payable on November 2, 2026, to shareholders of record as of October 2, 2026.
💰 This move reinforces Bristol Myers Squibb's ongoing strategy of returning value to shareholders through regular cash distributions.
🔬 The company reaffirmed its mission to deliver innovative medicines for serious diseases supported by global R&D investments.
Bullish Signals
Declared $0.63 quarterly dividend.
Maintained distribution cadence.
Bullish Signals
Bristol Myers Squibb declared a quarterly dividend of $0.63 per share, reinforcing its commitment to returning value to shareholders through consistent cash distributions.
The company maintained its established cadence of quarterly distributions, signaling financial stability and confidence in future cash flows.
Bristol Myers Squibb announced positive registrational results from its Phase 2 QUINTESSENTIAL study evaluating arlocabtagene autoleucel in heavily pretreated multiple myeloma patients. The trial met both its primary and secondary endpoints, demonstrating the efficacy of this CAR T therapy for a difficult-to-treat patient population.
The company reported that the safety profile of the treatment aligns with expectations based on prior data. These results are set to be presented at an upcoming medical conference, providing further validation for the drug's potential in the oncology market.
✅ Trial met primary and secondary endpoints in heavily pretreated multiple myeloma patients.
🛡️ CAR T therapy safety profile aligns with company expectations.
📅 Results will be presented at an upcoming medical conference.
📈 Bristol Myers Squibb announced positive registrational outcomes from its Phase 2 QUINTESSENTIAL study for arlocabtagene autoleucel.
✅ The trial met both primary and secondary endpoints in heavily pretreated multiple myeloma patients.
🛡️ The safety profile of the CAR T therapy aligns with company expectations.
📅 Results will be presented at an upcoming medical conference.
Bullish Signals
BMS Phase 2 QUINTESSENTIAL study met endpoints.
Drug showed efficacy in heavily pretreated myeloma.
Bullish Signals
Bristol Myers Squibb achieved positive results in its registrational Phase 2 QUINTESSENTIAL study for arlocabtagene autoleucel, meeting primary and secondary endpoints.
The drug demonstrated efficacy in heavily pretreated multiple myeloma patients, a challenging therapeutic area.
Bristol Myers Squibb (NYSE: BMY) reported encouraging mid-stage trial results for its experimental CAR-T cell therapy, arlo-cel, in patients with advanced multiple myeloma who have exhausted four prior treatment classes. The therapy met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in overall response rates, while also achieving a key secondary goal of complete elimination of detectable cancer in some patients.
The results strengthen BMY's position in the competitive oncology market, particularly within the difficult-to-treat multiple myeloma segment where unmet medical need remains high. Arlo-cel targets GPRC5D on cancer cells using a patient's own immune system, offering a potential new growth driver to diversify revenue beyond existing blockbuster medicines. The company plans to present full data at an upcoming medical conference, though detailed response rates and survival metrics have not yet been released.
Despite the positive mid-stage signals, analysts note that commercial success depends on translating these results into regulatory approval and sustained sales in a crowded landscape. Competition from other CAR-T therapies and newer immune-based treatments poses challenges, as does the practical complexity of CAR-T administration compared to oral or injectable alternatives. BMY must demonstrate clear advantages in effectiveness, durability, and safety to secure a meaningful market share.
While this development is viewed as a meaningful win for BMY's pipeline and long-term growth story, it is not yet considered a major commercial breakthrough. Investors are advised to await the detailed clinical data presentation to assess the durability of responses before judging the full potential of the asset. The article concludes that while risks remain regarding later-stage trials and competition, arlo-cel adds confidence to BMY's CAR-T program.
📈 Arlo-cel met primary goals in advanced multiple myeloma trial after four prior treatments.
🔬 Therapy showed significant response rates with some patients achieving complete cancer elimination.
⚠️ Commercial success depends on proving advantages over competing CAR-T therapies and new treatments.
📊 Program aims to diversify oncology revenue beyond current blockbuster medicines for BMY.
⚠️ Mid-stage results do not guarantee later-stage trial success or regulatory approval for arlo-cel.
📈 Bristol Myers Squibb's experimental CAR-T therapy arlo-cel met its primary goal in a mid-stage trial for advanced multiple myeloma patients who had failed four prior treatments.
🔬 The therapy achieved a statistically significant and clinically meaningful improvement in overall response rates, with some patients achieving complete elimination of detectable cancer.
📅 BMY plans to present full trial results at an upcoming medical conference, though detailed numbers on progression-free survival and safety have not yet been released.
💊 Arlo-cel targets GPRC5D on cancer cells by modifying a patient's own immune cells, addressing a significant unmet medical need in a difficult-to-treat population.
📉 The multiple myeloma market faces intense competition from existing CAR-T therapies and newer immune-based treatments, including recent strong results from AbbVie's etentamig.
⚠️ Commercial success for arlo-cel depends on demonstrating clear advantages in effectiveness, durability, safety, and treatment convenience against competing options.
📊 The program represents a potential new growth driver to diversify BMY's oncology revenue as the company seeks expansion beyond its current blockbuster medicines.
🛑 While mid-stage results lower development risk, they do not guarantee success in later-stage trials or regulatory approval for this cell therapy candidate.
Bullish Signals
Arlo-cel CAR-T therapy met primary endpoint in multiple myeloma trial.
Therapy achieved complete cancer elimination in some patients.
Results strengthen oncology market position and diversify revenue.
Risk Factors
Clinical data pending creates investor uncertainty on durability.
Complex CAR-T admin requires proving advantage over rivals.
Bullish Signals
Bristol Myers Squibb's experimental CAR-T therapy arlo-cel met its primary endpoint in a mid-stage trial, showing statistically significant and clinically meaningful improvement in overall response rates for advanced multiple myeloma patients.
The therapy achieved a key secondary goal of complete elimination of detectable cancer in some patients, suggesting the potential for deep responses in a difficult-to-treat population.
Encouraging trial results strengthen BMY's position in the competitive oncology market and provide another potential long-term growth asset to diversify revenue beyond existing blockbuster medicines.
Risk Factors
Detailed clinical data, including specific response rates, progression-free survival, overall survival, and detailed safety profiles, have not yet been released, leaving investors uncertain about the durability of the therapy's benefits.
Practical issues associated with CAR-T therapies, such as complex administration processes compared to non-CAR-T alternatives, require BMY to demonstrate sufficient advantages in effectiveness and treatment experience to stand out.
Bristol Myers Squibb (BMY) reported strong quarterly financial results, beating analyst expectations with earnings per share of $2.04 against a consensus of $1.60 and revenue rising 5.7% year-over-year to $12.97 billion. The company maintains a robust balance sheet with a quick ratio of 1.38 and a market capitalization of approximately $136.56 billion, while offering shareholders a quarterly dividend of $0.63 for an annualized yield of 3.8%.
Institutional investor activity shows mixed signals regarding the stock's near-term trajectory. Mid American Wealth Advisory Group reduced its position by 27.8%, selling over 22,000 shares, while several other funds including Swiss RE and Darwin Wealth Management initiated new positions valued between $25,000 and $32,000 during the quarter. Analyst consensus remains a 'Moderate Buy' with a price target of $66.06, though individual targets vary from $59 to $73.
The company faces specific headwinds including safety concerns that led to a pause in zola-cel autoimmune cell-therapy trials and looming patent expiries for legacy drugs like Eliquis and Opdivo. Conversely, the stock is supported by strong margins, low valuation metrics relative to peers, and positive analyst sentiment following recent upgrades from Sanford Bernstein and JPMorgan Chase.
Bristol Myers Squibb is expanding its pipeline into new therapeutic areas, such as a Phase 2 trial for depression therapy, aiming to offset declines in older medicines. While insider selling occurred with SVP Phil Holzer reducing his holdings, the broader institutional ownership stands at 76.41%, indicating continued significant interest from major investors despite sector-wide pressure.
📈 BMY EPS beat estimates at $2.04 with revenue up 5.7%.
💰 Quarterly dividend of $0.63 offers a 3.8% annualized yield.
🔬 Enrollment paused in zola-cel trials due to inflammatory safety concerns.
⚠️ Risks include legacy drug declines for Opdivo and Eliquis patents.
📈 Analysts upgraded BMY with a consensus price target of $66.06.
📈 BMY reported quarterly EPS of $2.04, significantly beating the $1.60 consensus estimate, while revenue grew 5.7% year-over-year to $12.97 billion.
💰 The company pays a quarterly dividend of $0.63, representing a 3.8% annualized yield with a payout ratio of 55.51%.
📉 Mid American Wealth Advisory Group cut its BMY position by 27.8%, selling 22,416 shares and retaining approximately $3.35 million worth of stock.
🔬 Bristol Myers Squibb paused enrollment in zola-cel autoimmune cell-therapy trials following the identification of inflammatory safety concerns.
⚠️ Investors face risks from legacy-drug declines, specifically Opdivo, and future patent expiry for Eliquis.
📊 The stock carries a 'Moderate Buy' consensus rating with a price target of $66.06, though analyst targets range widely from $59 to $73.
🚀 BMY is expanding its pipeline into the depression market via a new Phase 2 trial evaluating a therapy in that large potential market.
📈 Analyst sentiment improved recently with upgrades from Sanford Bernstein and JPMorgan Chase raising price targets and ratings.
💼 Institutional ownership remains high at 76.41%, with several funds like Swiss RE initiating new positions valued around $25,000.
📉 Insider selling occurred as SVP Phil Holzer sold 500 shares, reducing his ownership by 2.88% in a transaction worth $33,750.
Bullish Signals
EPS beat at $2.04 vs $1.60 consensus with 5.7% revenue growth.
Defensive profile offers 3.8% dividend yield on low valuation.
Strong liquidity shown by quick ratio of 1.38 and 18.87% net margin.
Upgrades from Sanford Bernstein and JPMorgan raise price target to $73.
New depression therapy trial expands growth into large potential market.
Risk Factors
Zola-cel trials paused due to serious inflammatory side effects.
Revenue risks from Opdivo declines and Eliquis patent expiry.
Mid American Wealth reduced stake by 27.8% selling 22k shares.
Healthcare sector downturn adds pressure to stock performance.
SVP Phil Holzer sold 500 shares in late August.
Bullish Signals
Bristol Myers Squibb beat earnings expectations with EPS of $2.04 versus the $1.60 consensus and revenue growth of 5.7% to $12.97 billion.
The company offers a defensive income profile with a quarterly dividend of $0.63 yielding 3.8% annually and a low valuation relative to peers.
Strong financial health is evidenced by a quick ratio of 1.38, current ratio of 1.53, and a net margin of 18.87%.
Analyst sentiment turned more bullish recently with Sanford Bernstein upgrading to 'outperform' and JPMorgan raising its price target to $73.
The company is diversifying growth by launching a Phase 2 trial for depression therapy, expanding into a large potential market.
Institutional confidence is supported by new positions from funds like Swiss RE and Darwin Wealth Management totaling over $50,000 in the quarter.
Risk Factors
Bristol Myers Squibb paused its zola-cel autoimmune cell-therapy trials after safety surveillance identified serious inflammatory side effects.
The company faces significant revenue risks from legacy-drug declines, including Opdivo, and the future patent expiry of Eliquis.
Mid American Wealth Advisory Group significantly reduced its stake by 27.8%, selling over 22,000 shares in the second quarter.
The wider healthcare sector traded lower recently, adding industry-level pressure to BMY's stock performance.
Insider selling activity was noted as SVP Phil Holzer sold 500 shares of the company's stock in late August.
Bristol-Myers Squibb (NYSE:BMY) is identified as a high-priority candidate for technical breakout strategies, achieving a perfect technical rating of 10 out of 10 and a setup quality score of 9 out of 10. The stock demonstrates strong trend strength across multiple timeframes with major moving averages pointing higher, indicating it has successfully attracted market participants and is building a base near a logical entry point rather than being overextended.
The analysis outlines a specific trading plan for BMY, suggesting a buy stop order at $68.10 just above the resistance zone and a stop-loss at $65.90. This structure defines a potential loss of 2.20 points (approximately 3.23%) per trade, with a suggested position size that limits total portfolio risk to around 0.81%. The setup implies that prices have been consolidating, providing a defined trigger for entry and a clear failure point if the stock fails to reach the buy stop.
Beyond technical metrics, BMY is highlighted for generating strong free cash flow relative to its market price and belonging to a more stable, less cyclical segment of the market. The company has exhibited more stable recent price behavior compared to typical market movers, reinforcing its status as a leading stock with a better chance of following through after breaking resistance levels.
📈 BMY achieves perfect technical rating of 10/10 with strong trend strength.
🛡️ Trade limits loss to 3.23% and portfolio risk to 0.81%.
📉 Major moving averages point higher as stock builds a base.
📈 Bristol-Myers Squibb achieves a perfect technical rating of 10 out of 10 and a setup quality score of 9 out of 10, confirming strong trend strength and a logical entry base.
📊 The stock exhibits stable recent price behavior and belongs to a less cyclical market segment compared to typical movers.
💰 BMY generates strong free cash flow relative to its current market price, supporting its financial stability.
🎯 A specific trading plan suggests a buy stop at $68.10 above resistance with a stop-loss at $65.90.
🛡️ The defined trade structure limits potential loss to 2.20 points (3.23%) and caps total portfolio risk at approximately 0.81%.
📉 Major moving averages are pointing higher, indicating that the stock is building a base rather than being overextended.
Belongs to stable segment with less cyclical behavior than typical movers.
Bullish Signals
Bristol-Myers Squibb achieves a perfect technical rating of 10 out of 10 and a setup quality score of 9 out of 10, confirming strong trend strength and a logical entry base.
The stock generates strong free cash flow relative to its market price, indicating robust financial health.
BMY belongs to a more stable, less cyclical segment of the market with more stable recent price behavior than typical market movers.
Nykredit A/S purchased 506,199 shares of Bristol Myers Squibb (BMY) in the second quarter, valued at approximately $29.2 million, contributing to institutional ownership of 76.41%. The company reported strong quarterly financials with earnings per share of $2.04, beating estimates of $1.60, and revenue rising 5.7% year-over-year to $12.97 billion.
Bristol Myers Squibb maintains a quarterly dividend of $0.63 per share, yielding 3.7%, while analysts hold a consensus 'Moderate Buy' rating with an average price target of $66.06. Recent positive sentiment is driven by encouraging long-term data for the heart-failure drug Camzyos from the EXPLORER-LTE study, which supports its growth trajectory.
However, the company faces pipeline risks as it voluntarily paused enrollment in zola-cel autoimmune cell-therapy trials due to inflammatory side effects. This pause raises concerns about the safety profile of experimental therapies and may increase scrutiny on trial-disclosure practices, particularly following similar halts by Novartis.
Analyst sentiment remains mixed with recent rating changes: Sanford C. Bernstein upgraded BMY to 'outperform,' Raymond James initiated a 'strong-buy' rating, and Piper Sandler assigned an 'overweight' rating, while Jefferies cut its rating to 'hold.' The stock trades at a P/E ratio of 14.99 with a market capitalization of $139.03 billion.
📈 Nykredit acquired $29.2M BMY position in Q2.
💰 EPS beat estimates at $2.04 vs $1.60.
📈 Revenue rose 5.7% YoY to $12.97B.
⚠️ Zola-cel trials paused due to inflammatory side effects.
🔬 Camzyos long-term data supports positive investor sentiment.
📈 Nykredit A/S acquired a new position in BMY worth approximately $29.2 million during the second quarter.
💰 Bristol Myers Squibb reported quarterly EPS of $2.04, significantly beating analyst estimates of $1.60.
📈 Revenue increased 5.7% year-over-year to reach $12.97 billion in the latest quarter.
💸 The company pays a quarterly dividend of $0.63 per share, offering a 3.7% annualized yield.
🔬 Positive investor sentiment is supported by encouraging long-term data for Camzyos from the EXPLORER-LTE study.
⚠️ Bristol Myers Squibb paused enrollment in zola-cel autoimmune trials due to inflammatory side effects.
📉 The trial pause raises concerns about the risk profile of experimental cell therapy programs.
🔍 Novartis and BMY halted autoimmune trials following deaths or serious side effects, reinforcing safety concerns.
📊 Analysts rate BMY a 'Moderate Buy' with an average price target of $66.06.
🚀 Sanford C. Bernstein upgraded BMY from 'market perform' to 'outperform' in late August.
🔥 Raymond Financial initiated coverage with a 'strong-buy' rating on the stock.
⚖️ Piper Sandler initiated coverage assigning an 'overweight' rating to Bristol Myers Squibb shares.
📉 Jefferies Financial Group cut its rating from 'buy' to 'hold' in late August.
📈 The stock opened at $68.06, trading above its 50-day and 200-day moving averages.
🏢 Corporate insiders own a minimal 0.05% of the company's outstanding shares.
Bullish Signals
Bristol Myers Squibb reported quarterly EPS of $2.04, beating analyst estimates of $1.60 by $0.44.
Revenue rose 5.7% year-over-year to $12.97 billion, exceeding the consensus estimate of $11.74 billion.
Encouraging long-term data for Camzyos from the EXPLORER-LTE study supports renewed investor interest and growth expectations.
Institutional ownership remains strong at 76.41%, with Nykredit A/S adding a $29.2 million position in Q2.
Analysts have upgraded or initiated coverage with bullish ratings, including 'outperform' from Sanford C. Bernstein and 'strong-buy' from Raymond James.
The stock trades at a P/E ratio of 14.99 with a market capitalization of $139.03 billion, reflecting solid valuation metrics.
Analysts forecast FY 2026 EPS between 6.75 and 7.00, indicating continued growth expectations.
Risk Factors
Bristol Myers Squibb voluntarily paused enrollment in zola-cel autoimmune trials after inflammatory side effects emerged.
The trial pause raises concerns about the therapy's risk profile and may delay a potentially important pipeline program.
Broader reporting that Novartis and BMY halted autoimmune trials following deaths or serious side effects reinforces safety concerns.
RBC Capital maintained a 'Hold' rating, noting that the stock's strong run may already incorporate much of the favorable news.
Corporate insider SVP Phil M. Holzer sold 500 shares in late August, representing a 2.88% decrease in his position.
Simply Wall St analysis suggests Bristol-Myers Squibb (BMY) stock is undervalued by approximately 46.3%, trading at $63.83 per share against a Discounted Cash Flow (DCF) intrinsic value estimate of roughly $119. The company has delivered a 38.1% gain over the past year, yet valuation metrics including P/E multiples indicate it remains cheaper than industry and peer averages.
The analysis highlights specific catalysts supporting future cash flows, including the FDA's accelerated approval of ZENBEXUS for multiple myeloma and plans to build a US$2.3 billion manufacturing campus in Houston. Conversely, risks include a revived lawsuit regarding Celgene contingent value rights worth US$6.7 billion and significant upcoming patent cliffs for blockbuster drugs like Eliquis and Opdivo.
Valuation comparisons show BMY trading at a P/E of 14.0x, which is below the Pharmaceuticals industry average of 16.9x and significantly lower than the peer group average of 58.4x. The model implies a fair P/E ratio of 18.2x, suggesting the market is pricing in lower earnings multiples than warranted by the company's size and profitability profile.
The article concludes that while the discount may reflect genuine mispricing offering a margin of safety for investors, it could also serve as compensation for legal overhangs and patent expiries. The key determinant for future performance will be whether BMY can sustain its cash flows by offsetting revenue erosion from generic competition with its robust pipeline and strategic investments.
📊 BMY estimated 46.3% undervalued with $119 intrinsic value.
📊 Bristol-Myers Squibb (BMY) is estimated to be 46.3% undervalued based on a Discounted Cash Flow model projecting an intrinsic value of approximately $119 per share.
📈 The stock has delivered a strong 38.1% return over the past year, though recent gains have not fully eliminated potential upside according to current valuation signals.
💊 The FDA granted accelerated approval for ZENBEXUS to treat multiple myeloma, providing a new revenue stream and supporting future cash flow projections.
🏗️ The company plans to construct a US$2.3 billion manufacturing campus in Houston to support production capabilities.
⚖️ A revived legal dispute concerning Celgene contingent value rights poses a potential financial risk with an exposure of approximately US$6.7 billion.
📉 BMY trades at a P/E ratio of 14.0x, which is below the industry average of 16.9x and far below the peer group average of 58.4x.
⏳ Upcoming patent cliffs for major drugs like Eliquis (generic in 2028) and Opdivo present risks to long-term revenue growth due to generic and biosimilar competition.
🎯 The DCF model assumes last twelve month free cash flow of about US$11.5b, with projections holding steady rather than assuming aggressive expansion.
📉 Community sentiment is divided between a bull case citing breakthrough partnerships like BioNTech and a bear case warning of patent erosion risks.
Bullish Signals
38.1% gain over past year.
FDA approved ZENBEXUS asset.
$2.3B Houston manufacturing campus.
P/E 14.0x vs industry 16.9x.
Fair P/E 18.2x implies discount.
Risk Factors
Revived lawsuit exposes company to ~US$6.7 billion financial risk.
Patent cliffs for Eliquis (2028) and Opdivo raise generic competition risks.
Conservative DCF model limits upside if growth falls short of expectations.
Bullish Signals
The stock is trading at a significant discount to its estimated intrinsic value, offering a potential margin of safety for valuation-focused investors.
Recent share price performance shows a 38.1% gain over the past year, indicating improving market sentiment toward the company.
The FDA's accelerated approval of ZENBEXUS adds a new therapeutic asset to the pipeline, supporting long-term revenue expectations.
The planned US$2.3 billion manufacturing campus in Houston demonstrates commitment to operational capacity and future growth.
Current P/E multiple of 14.0x is substantially lower than both the industry average (16.9x) and peer group average (58.4x), suggesting undervaluation relative to peers.
The DCF model implies a fair P/E ratio of 18.2x, indicating the market is currently pricing earnings at a discount to the company's fundamental profile.
Risk Factors
A revived lawsuit regarding Celgene contingent value rights creates a specific legal and financial risk with an exposure of approximately US$6.7 billion.
Significant upcoming patent cliffs for blockbuster drugs like Eliquis (generic in 2028) and Opdivo raise the risk of generic and biosimilar competition impacting long-term revenue.
The DCF model assumes cash flows will broadly hold around current levels rather than aggressive expansion, which may limit upside potential if growth is slower than expected.
Bristol-Myers Squibb (BMY) concluded the second quarter with a strong performance, driving its stock price to a 52-week high of $64.96 on June 28. The company reported Q2 revenue of $12.97 billion, representing a 12.9% increase quarter-over-quarter. Non-GAAP earnings per share surged 39.7% year-over-year and 29.1% quarter-over-quarter to reach $2.04, significantly beating the author's base case scenario.
Following the earnings release, Bristol-Myers Squibb raised its full-year 2026 diluted EPS guidance from a previous range of $6.05-$6.35 to a new target of $6.75-$7. The rally is attributed to promising efficacy data for Iza-Bren in triple-negative breast cancer and sustained strong demand for key products Opdivo Qvantig and Breyanzi. The article concludes that the stock's risk/reward profile remains attractive despite recent gains.
The author, representing Allka Research, highlights the conservative investment approach and substantial returns associated with the company within the pharmaceutical sector. While the text includes standard disclosures regarding a beneficial long position in LEGN and general Seeking Alpha disclaimers, the core financial narrative focuses on BMY's robust earnings beat and upward revision of profit expectations.
📈 BMY stock hit 52-week high of $64.96 on June 28.
💰 Q2 revenue reached $12.97 billion, up 12.9% quarter-over-quarter.
🚀 Non-GAAP EPS rose 39.7% year-over-year to $2.04.
📊 Company raised 2026 diluted EPS guidance to $6.75-$7.
💉 Strong demand drives Opdivo Qvantig and Breyanzi sales.
📈 BMY stock reached a 52-week high of $64.96 on June 28 following Q2 results.
Institutional investors have significantly adjusted their positions in Bristol Myers Squibb (NYSE:BMY) during the first quarter and fourth quarter of recent trading periods. While 44 Wealth Management LLC reduced its stake by 23.9%, trimming holdings to approximately $2.68 million, several major funds increased their exposure. Norges Bank initiated a new position valued at roughly $1.95 billion, while AQR Capital Management grew its stake by 172.6% to hold over $1.39 billion in shares.
Other notable institutional activity includes Bank of New York Mellon raising its holdings by 47.0% and Geode Capital Management increasing its position by 13.1%. Man Group plc also lifted its stake by 280.4% during the second quarter. Collectively, hedge funds and other institutional investors now own approximately 76.41% of the company's outstanding stock, indicating strong continued interest from large-scale capital despite some individual reductions.
The article provides detailed financial metrics for Bristol Myers Squibb, noting a market capitalization of $126.70 billion and a current share price opening at $62.05. The company maintains a dividend yield of 4.1% with an annualized payout of $2.52 per share, supported by a payout ratio of 70.79%. Analyst consensus remains mixed, with an average rating of 'Hold' and a consensus price target of $61.25, though individual targets vary from $54 to $67.
📉 Wealth Management LLC sold shares, holding 44,227 valued at $2.68 million.
📈 Norges Bank added $1.95 billion stake in Q4.
📈 AQR Capital increased holdings by 172.6% to $1.39 billion.
💰 Market cap is $126.70 billion with P/E of 17.43.
👥 Analysts rate 'Hold' with a $61.25 price target.
📉 44 Wealth Management LLC reduced its Bristol Myers Squibb stake by 23.9%, holding 44,227 shares valued at $2.68 million as of the latest filing.
📈 Norges Bank established a new position in BMY worth approximately $1.95 billion during the fourth quarter.
📈 AQR Capital Management increased its holdings by 172.6%, now owning 25,796,905 shares valued at $1.39 billion.
📈 Bank of New York Mellon raised its stake by 47.0% to own 24,495,875 shares worth $1.32 billion.
📈 Geode Capital Management lifted its position by 13.1%, holding 52,638,346 shares valued at $2.84 billion.
📈 Man Group plc increased its stake by 280.4% in the second quarter, owning 7,465,845 shares worth $345 million.
💰 Bristol Myers Squibb has a market cap of $126.70 billion and trades with a P/E ratio of 17.43.
💸 The company announced a quarterly dividend of $0.63 per share, payable on August 3rd to shareholders of record on July 2nd.
📊 Institutional ownership stands at 76.41%, with the stock trading between a 52-day average of $57.49 and a 200-day average of $58.03.
👥 Analyst sentiment is mixed, with an average rating of 'Hold' and a consensus price target of $61.25.
Bullish Signals
Major investors like Norges Bank increased stakes significantly.
Attractive 4.1% dividend yield with manageable 70.79% payout ratio.
Strong 76.41% institutional ownership signals confidence in long-term prospects.
Risk Factors
Analyst consensus Hold targets $61.25, below recent $62.05 open.
Cantor Fitzgerald neutral target is lower at $54.00.
Weiss Ratings downgraded to hold (c) showing caution.
Bullish Signals
Major institutional investors including Norges Bank, AQR Capital Management, and Bank of New York Mellon have significantly increased their stakes in the company.
The stock offers an attractive 4.1% dividend yield with a consistent payout history and a manageable 70.79% payout ratio.
Strong institutional ownership at 76.41% suggests confidence from large capital managers in the company's long-term prospects.
Risk Factors
Analyst consensus is currently 'Hold' with a price target of $61.25, which is below the recent opening price of $62.05.
Cantor Fitzgerald maintains a neutral rating with a lower price target of $54.00 compared to other analysts.
Weiss Ratings recently downgraded the stock from 'hold (c+)' to 'hold (c)', indicating some caution among rating agencies.
Erste Group Bank analyst H. Engel has lowered its full-year 2027 earnings per share (EPS) forecast for Bristol Myers Squibb to $6.10, down from a previous estimate of $6.12. This adjustment places the company below the broader consensus estimate of $6.34. The report was issued on July 15th, signaling a shift in analyst sentiment regarding future profitability expectations for the biopharmaceutical firm.
Recent market activity shows mixed signals from other major financial institutions. While Bank of America maintained a 'buy' rating despite cutting its price target to $66.00, Cantor Fitzgerald set a lower neutral target at $54.00. The stock currently trades with a consensus 'Hold' rating and a target price of $61.25, trading near its 52-week high of $62.89 but well above its 52-week low of $42.52.
Fundamental performance remains robust based on the latest quarterly results released on April 30th. Bristol Myers Squibb reported EPS of $1.58, beating analyst expectations of $1.42, with revenue reaching $11.49 billion, a 2.6% increase year-over-year. The company maintains strong financial health with a return on equity of 64.87% and a net margin of 15.01%, while offering an annualized dividend yield of 4.2%.
Institutional ownership continues to grow significantly among major asset managers. Vanguard Group, State Street Corp, Geode Capital Management, Norges Bank, and AQR Capital Management all increased their holdings in the fourth quarter. Notably, AQR Capital Management boosted its position by 172.6%, while institutional investors collectively own 76.41% of the company's outstanding shares.
📉 Erste Group cut FY2027 EPS estimate to $6.10 from $6.12.
💰 Q1 2026 EPS hit $1.58, beating the $1.42 consensus.
📈 Revenue reached $11.49 billion, up 2.6% year-over-year.
🏦 AQR Capital raised stake by 172.6% in Q4.
💵 Quarterly dividend of $0.63 yields 4.2% annually.
📉 Erste Group Bank analyst H. Engel cut FY2027 EPS estimates for Bristol Myers Squibb to $6.10 from $6.12.
📊 The stock currently holds a consensus 'Hold' rating with an average target price of $61.25 across major banks.
💰 Q1 2026 results showed strong performance with $1.58 EPS, beating the $1.42 consensus estimate.
📈 Revenue for the quarter reached $11.49 billion, representing a 2.6% year-over-year increase.
🏦 Institutional investors increased stakes in Q4, with AQR Capital Management raising its position by 172.6%.
💵 The company declared a quarterly dividend of $0.63 per share, yielding 4.2% annually to shareholders.
📉 Bank of America lowered its price objective to $66.00 while maintaining a 'buy' rating on the stock.
📉 Cantor Fitzgerald restated a neutral rating with a lower target price of $54.00 for the shares.
🏛️ The firm maintains a strong balance sheet with a debt-to-equity ratio of 2.10 and a quick ratio of 1.28.
🧬 Bristol Myers Squibb focuses its pipeline on oncology, hematology, immunology, and cardiovascular diseases.
Bullish Signals
Q1 EPS $1.58 beat consensus $1.42.
Net margin 15.01% and ROE 64.87%.
Revenue $11.49B up 2.6% year-over-year.
Institutional investors increased holdings in Q4.
AQR stake surged 172.6% to 16M shares.
Dividend yield 4.2% with 70.79% payout.
Risk Factors
Erste Group lowered FY2027 EPS forecast to $6.10.
Cantor Fitzgerald target price of $54.00 below current price.
Bank of America reduced objective from $67.00 to $66.00.
Bullish Signals
Bristol Myers Squibb reported Q1 2026 EPS of $1.58, which significantly topped analyst consensus estimates of $1.42.
The company achieved a net margin of 15.01% and a return on equity of 64.87% during the quarter.
Quarterly revenue of $11.49 billion exceeded expectations of $10.93 billion, showing growth of 2.6% year-over-year.
Major institutional investors including Vanguard Group, State Street Corp, and Geode Capital Management increased their holdings in the fourth quarter.
AQR Capital Management aggressively increased its stake by 172.6%, adding over 16 million shares to its portfolio.
The company offers a substantial annualized dividend yield of 4.2% with a payout ratio of 70.79%.
Risk Factors
Erste Group Bank analyst lowered the FY2027 EPS forecast to $6.10, indicating reduced growth expectations for the coming year.
Cantor Fitzgerald set a neutral rating with a target price of $54.00, which is below the current trading price.
Bank of America reduced its price objective from $67.00 to $66.00 despite maintaining a buy rating.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
